Pharmaceutical Technology E-Alert:
Having trouble viewing this e-mail? Click here.
You are subscribed to %%list.name%% as %%emailaddr%%.
Click here to unsubscribe or edit your member profile.
  Pharmaceutical Technology Europe E-Alert
 
2 December 2011

IN THIS ISSUE
Vioxx settlements
Elan and Cambridge
EMA subgroup workshop
Gilead acquisition

 
Merck settles Vioxx claims with 950 million dollars
The US pharmaceutical company Merck & Co. has agreed to pay $950 million to resolve criminal charges and civil claims related to its promotion and marketing of the painkiller Vioxx. More...
 
Elan and University of Cambridge Launch New Research Center
Elan and the University of Cambridge have launched a center for innovation and drug discovery that will focus on translational research into therapies for Alzheimer’s and Parkinson’s diseases. More...
 
EMA hosts subgroup analysis workshop; invites Esubmission gateway registrations
The EMA brought together European and US expert representatives from regulatory authorities, academia, industry and a health-technology-assessment agency on Nov. 18, 2011 to discuss the use and importance of subgroup analysis in the assessment of clinical trials. More...
 
Gilead acquires Pharmasset for $11 billion
Gilead Sciences has agreed to acquire Pharmasset for $137 per share in cash, or a total of approximately $11 billion. More...
 
Join our community on LinkedIn
Want to discuss any of this week’s news stories or any other hot topics in the industry? Then why not join our group on LinkedIn? More...
Key Topics:
Latest blog posts
Making it skin deep
Let's fight adulteration with information
Deep (clean) discussion
More blog posts

Latest articles
Under continuous consideration
Threats and opportunities in cardiovascular health
Focus on standardisation, quality by design and regulatory GMP
More articles

Upcoming events
Serialization 2/0 - Getting Prepared for the Future of Pharma Supply Chain Security (13 December | Webinar)
Fast and Effective Cell Culture Media Development Using Design of Experiment (DoE) (17 January | Webinar)
European Pre-Filled Syringes (18–19 January | UK)
More events

Products/Service Profiles
Oxoid

QC Organisms for performance qualification of culture media
Quanti-Cult Plus™ quality control micro-organisms are ideal for use in pharmaceutical applications such as growth promotion testing and method validation. They are convenient to use with each aliquot guaranteed to deliver <100 CFU and only 3 passages from the ATCC® strain. Once reconstituted they are stable for up to 8 hours at 2-8C. Read more

 
Sterilin

Superior quality pipettes for endotoxin testing
Sterilin single-use, serological pipettes are certified non-pyrogenic to a lower level than ever before (0.01EU/ml), making them ideal for pharmaceutical and medical device manufacturers to use when ensuring that their products are free from endotoxin contamination. Read more


Future Webcasts

Vetter's Chicago Facility Fully Operational
In 2010, Vetter brought you up to date on the company’s plans to expand its Vetter Development Service operations by opening its first manufacturing site outside of Germany.  Just recently, Vetter announced that the site, located in Chicago at the Illinois Science + Technology Park in Skokie, is fully operational. Read more


 
Survey
What is driving manufacturers to reformulate or reinvent currently marketed solid dose pharmaceutical products?
Need to renew patents 49%
 
Availability of new excipients 11%
     
Opportunity to improve efficacy and patient compliance 40%

This week we would like to know...

Do you support a generic-drug user fee for industry?

Click here to vote

Contact Us
Click here to contact editorial.

Click here to contact sales.

 
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact
information available to third parties for marketing purposes, please contact us by emailing [email protected] or by mail
at Advanstar Communications Inc., Bridgegate Pavilion, 4A Chester Business Park, Wrexham Road, Chester, CH4 9QH, UK.